Lack of tocilizumab effect on mortality in COVID19 patients

Gregory E. Holt, Mayank Batra, Mukunthan Murthi, Shweta Kambali, Kayo Santos, Maria Virginia Perez Bastidas, Huda Asif, Sara Haddadi, Sixto Arias, Mehdi Mirsaeidi

Research output: Contribution to journalArticlepeer-review

Abstract

Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn’t imply causality however lack of improvement by tocilizumab requires further clinical trial alterations.

Original languageEnglish (US)
Article number17100
JournalScientific reports
Volume10
Issue number1
DOIs
StatePublished - Dec 1 2020

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Lack of tocilizumab effect on mortality in COVID19 patients'. Together they form a unique fingerprint.

Cite this